Sustained efficacy of repeat treatment courses of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs

被引：0

作者：

Emery, P. ^{[1
]}

Furst, D. E. ^{[2
]}

Ferraccioli, G. ^{[3
]}

Udell, J. ^{[4
]}

van Vollenhoven, R. F. ^{[5
]}

Rowe, K. ^{[6
]}

Agarwal, S. ^{[7
]}

Shaw, T. ^{[6
]}

机构：

[1] Leeds Gen Infirmary Leeds, Leeds, W Yorkshire, England

[2] Univ Calif Los Angeles, Rheumatol Clin Res Ctr, Los Angeles, CA USA

[3] Catholic Univ, Rome, Italy

[4] Arthritis Grp, Philadelphia, PA USA

[5] Karolinska Univ Hosp, Stockholm, Sweden

[6] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England

[7] Genentech Inc, San Francisco, CA 94080 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：430 / 430

页数：1

共 50 条

[1] Repeated treatment courses of rituximab produce sustained efficacy in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
Emery, Paul
Furst, Daniel E.
Ferraccioli, Gianfranco
Udell, James
van Vollenhoven, Ronald F.
Rowe, Karen
Shaw, Tim
[J]. RHEUMATOLOGY, 2008, 47 : II46 - II46
[2] Repeated treatment courses of rituximab produce sustained efficacy in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
Emery, Paul
Khraishi, Majed
Furst, Daniel
Ferracioli, Gianfranco
Udell, James
van Vollenhoven, Ronald
Rowe, Karen
Agarwal, Sunil
Shaw, Tim
[J]. JOURNAL OF RHEUMATOLOGY, 2008, 35 (06) : 1182 - 1182
[3] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
Emery, P.
van Vollenhoven, R. F.
Furst, D. E.
Ferraccioli, G.
Udell, J.
Rowe, K.
Agarwal, S.
Shaw, T.
[J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 40 - 41
[4] Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs
Emery, P.
Furst, D. E.
Ferraccioli, G.
Udell, J.
Van Vollenhoven, R. F.
Rowe, K.
Agarwa, S.
Shaw, T.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 58 - 58
[5] Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
Pavelka, Karel
Kavanaugh, Arthur F.
Rubbert-Roth, Andrea
Ferraccioli, Gianfranco
[J]. RHEUMATOLOGY, 2012, 51 : V12 - V21
[6] Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs.
Emery, P.
Furst, D. E.
Ferraccioli, G.
Udell, J.
van Vollenhoven, R. F.
Rowe, K.
Agarwal, S.
Shaw, T.
[J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S228 - S228
[7] TREATMENT PATTERNS, PERSISTENCE, AND DURABILITY IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS)
Dore, Robin K.
Antonova, Jenya
Burudpakdee, Chakkarin
Wang, Xin
Ozbay, Burak
Genovese, Mark C.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1135 - 1136
[8] EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Zeng, X.
Liu, Y.
Hu, J.
Li, J.
Wang, Y.
Zhao, D.
Wu, L.
Xiao, Z.
Li, Z.
Xu, J.
Meerwein, S.
Xie, Y.
Liang, P.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1324 - 1324
[9] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
KIRWAN, JR
CURREY, HLF
[J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
[10] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
Agarwal, S.
Zaman, T.
Handa, R.
[J]. SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692

← 1 2 3 4 5 →